melphalan and Thrombophlebitis

melphalan has been researched along with Thrombophlebitis* in 3 studies

Trials

1 trial(s) available for melphalan and Thrombophlebitis

Article	Year
Melphalan vs polymelphalanum in ovarian cancer patients resistant to cyclophosphamide: a tentative statistical approach to balance risks and benefits. European journal of cancer, 1977, Volume: 13, Issue:8 Topics: Cyclophosphamide; Drug Resistance; Female; Humans; Melphalan; Ovarian Neoplasms; Risk; Thrombocytopenia; Thrombophlebitis	1977

Other Studies

2 other study(ies) available for melphalan and Thrombophlebitis

Article	Year
Peptichemio in advanced breast cancer: a clinical evaluation in 32 patients. Cancer treatment reports, 1986, Volume: 70, Issue:5 A clinical evaluation of peptichemio (40-45 mg/m2/day for 3 days every 3-4 weeks) was conducted in 32 patients with advanced breast cancer, 28 of whom were evaluable for both toxicity and response. The overall response rate was 18% (one complete remission and four partial remissions), with a median duration of 4 months (range, 2-6). The major side effects were cumulative myelotoxicity, phlebitis, mild nausea, and vomiting. A posttreatment heparin infusion was used to prevent phlebitis. Topics: Breast Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Hematologic Diseases; Heparin; Humans; Melphalan; Middle Aged; Neoplasm Metastasis; Peptichemio; Thrombophlebitis	1986
Perfusion treatment for malignant melanoma of the extremity. Archivum chirurgicum Neerlandicum, 1970, Volume: 22, Issue:2 Topics: Amputation, Surgical; Bone Marrow Diseases; Chemotherapy, Cancer, Regional Perfusion; Extracorporeal Circulation; Extremities; Fascia; Female; Hepatitis B; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Melphalan; Methods; Necrosis; Neoplasm Recurrence, Local; Neuritis; Prognosis; Thrombophlebitis	1970

Article

Year

Peptichemio in advanced breast cancer: a clinical evaluation in 32 patients.

Cancer treatment reports, 1986, Volume: 70, Issue:5

A clinical evaluation of peptichemio (40-45 mg/m2/day for 3 days every 3-4 weeks) was conducted in 32 patients with advanced breast cancer, 28 of whom were evaluable for both toxicity and response. The overall response rate was 18% (one complete remission and four partial remissions), with a median duration of 4 months (range, 2-6). The major side effects were cumulative myelotoxicity, phlebitis, mild nausea, and vomiting. A posttreatment heparin infusion was used to prevent phlebitis.

Topics: Breast Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Hematologic Diseases; Heparin; Humans; Melphalan; Middle Aged; Neoplasm Metastasis; Peptichemio; Thrombophlebitis

1986

Perfusion treatment for malignant melanoma of the extremity.

Archivum chirurgicum Neerlandicum, 1970, Volume: 22, Issue:2

Topics: Amputation, Surgical; Bone Marrow Diseases; Chemotherapy, Cancer, Regional Perfusion; Extracorporeal Circulation; Extremities; Fascia; Female; Hepatitis B; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Melphalan; Methods; Necrosis; Neoplasm Recurrence, Local; Neuritis; Prognosis; Thrombophlebitis

1970